News & Events about Century Therapeutics Inc.
CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasiontechnology, IL-15 cytokine support and a safety switch ELiPSE-1 trial to test multi-dosing strategy for CAR iNK enabled by Allo-Evasionedits designed to resist 3 major ...
ADMA Biologics (NASDAQ:ADMA Get Rating) and Century Therapeutics (NASDAQ:IPSC Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, ...
Globe Newswire
3 months ago
- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy - - iPSC-derived CAR gamma delta T cells shown to effectively control solid tumors as monotherapy and in combination with a therapeutic antibody - - ...